n | SLE % (95% CI) | CLE % (95% CI) | SCl % (95% CI) | RA % (95% CI) | PM/DM % (95% CI) | pSS % (95% CI) | Other % (95% CI) | |
---|---|---|---|---|---|---|---|---|
CLE, cutaneous lupus without systemic involvement; ID, immunodiffusion; LIA, line immunoassay; PM/DM, polymyositis/dermatomyositis; pSS, primary Sjögren's syndrome; RA, rheumatoid arthritis; SCl, scleroderma; SLE, systemic lupus erythematosus. | ||||||||
SSA+ and/or SSB+ | 181 | 45.3 | 7.7 | 8.8 | 7.7 | 2.2 | 14.4 | 13.8 |
ID SSA+ and IDSSB+ | 27 | 66.7 (46.0 to 83.5) | 3.7 (0.1 to 19.0) | 3.7 (0.1 to 19.0) | 7.4 (0.9 to 24.3) | 0 | 18.5 (6.3 to 38.1) | 0 |
ID SSA+ and ID SSB− | 70 | 61.4 (49.0 to 72.8) | 5.7 (1.6 to 14.0) | 0 | 4.3 (0.9 to 12.0) | 0 | 15.7 (8.1 to 26.4) | 12.9 (6.1 to 23.0) |
ID SSA− and ID SSB+ | 21 | 14.3 (3.0 to 36.3) | 23.8 (8.2 to 47.2) | 0 | 14.3 (3.0 to 36.3) | 0 | 33.3 (14.6 to 57.0) | 14.3 (3.0 to 36.3) |
ID SSA− and ID SSB− | 63 | 28.6 (17.9 to 41.3) | 6.3 (1.8 to 15.5) | 23.8 (14.0 to 36.2) | 9.5 (3.6 to 19.6) | 6.3 (1.8 to 15.5) | 4.8 (1.0 to 13.3) | 20.6 (11.5 to 32.7) |
LIA+ |